bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
UPDATE: bluebird bio's (BLUE) Zynteglo Gets FDA Approval - List Price In-Line Says Analyst
August 17, 2022 4:22 PM EDT(Updated - August 17, 2022 4:23 PM EDT)
bluebird bio's (NASDAQ: BLUE) cell-based gene therapy, Zynteglo, has been approved for the treatment of adult and pediatric patients with beta-thalassemia by the U.S. Food and Drug Administration, it was announced Wednesday.
Beta-thalassemia is a type of inherited blood disorder that causes a reduction of normal hemoglobin and red blood cells in the blood. Zynteglo is the first cell-based gene therapy to treat the blood disorder.
Zynteglo is a one-time gene therapy product administered as a single dose. Its safety and effectiveness were established in... More
bluebird bio (BLUE) Resumes Trading, Up 20%
August 17, 2022 2:30 PM EDTbluebird bio (NASDAQ: BLUE) Resumes Trading, Up 20%
... Morebluebird bio (BLUE) to Resume Trading at 2:30 p.m.
August 17, 2022 2:10 PM EDTbluebird bio (NASDAQ: BLUE) to Resume Trading at 2:30 p.m.
... More